| scholarly article | Q13442814 |
| P50 | author | Nina Bhardwaj | Q101410016 |
| P2093 | author name string | Peter Lauer | |
| Keith S Bahjat | |||
| Edward Lemmens | |||
| Thomas W Dubensky | |||
| Dirk G Brockstedt | |||
| Weiqun Liu | |||
| Emmanuelle Godefroy | |||
| Mojca Skoberne | |||
| Alice Yewdall | |||
| Meredith Leong | |||
| Will Luckett | |||
| P2860 | cites work | MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity | Q44734702 |
| CTLA-4 blockade: unveiling immune regulation | Q45197614 | ||
| Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity | Q45247142 | ||
| Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma | Q45287769 | ||
| Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. | Q46020879 | ||
| Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2. | Q46507524 | ||
| Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation | Q46561915 | ||
| Vaccination with irradiated Listeria induces protective T cell immunity | Q46713884 | ||
| Distinct in vivo dendritic cell activation by live versus killed Listeria monocytogenes. | Q50769848 | ||
| A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients. | Q53643421 | ||
| IFN Regulatory Factor 3-Dependent Induction of Type I IFNs by Intracellular Bacteria Is Mediated by a TLR- and Nod2-Independent Mechanism | Q57174180 | ||
| Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells | Q57729519 | ||
| Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen | Q63436914 | ||
| CD8alpha+ dendritic cells are required for efficient entry of Listeria monocytogenes into the spleen | Q79207317 | ||
| Patient-specific dendritic-cell vaccines for metastatic melanoma | Q80259122 | ||
| Cytoplasmic entry of Listeria monocytogenes enhances dendritic cell maturation and T cell differentiation and function | Q80418717 | ||
| Tumor antigen expression in melanoma varies according to antigen and stage | Q82506715 | ||
| Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 | ||
| Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles | Q28249760 | ||
| Phenotypic analysis of antigen-specific T lymphocytes | Q28290058 | ||
| Immune activation of type I IFNs by Listeria monocytogenes occurs independently of TLR4, TLR2, and receptor interacting protein 2 but involves TNFR-associated NF kappa B kinase-binding kinase 1 | Q28511836 | ||
| In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens | Q29615098 | ||
| An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow | Q29615498 | ||
| Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. | Q33211563 | ||
| Dendritic cells maximize the memory CD8 T cell response to infection | Q33801974 | ||
| Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity | Q33946547 | ||
| Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors | Q34111725 | ||
| Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation | Q34125450 | ||
| Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory | Q34190038 | ||
| Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors | Q34315765 | ||
| NY-ESO-1: review of an immunogenic tumor antigen | Q34550142 | ||
| Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination | Q34648472 | ||
| Current developments in cancer vaccines and cellular immunotherapy | Q35153859 | ||
| Cytosolic entry controls CD8+-T-cell potency during bacterial infection | Q35217477 | ||
| Manipulating dendritic cell biology for the active immunotherapy of cancer | Q35825249 | ||
| Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. | Q35977037 | ||
| Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant | Q36973053 | ||
| Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 | ||
| Listeria-based cancer vaccines that segregate immunogenicity from toxicity | Q37535306 | ||
| Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes | Q37570109 | ||
| Listeria monocytogenes-infected human dendritic cells: uptake and host cell response | Q39516533 | ||
| Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy | Q40360718 | ||
| Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. | Q40376308 | ||
| Bacterial delivery of functional messenger RNA to mammalian cells | Q40433335 | ||
| Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy | Q40542690 | ||
| CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes | Q40669542 | ||
| Toll-like receptor 2 is required for optimal control of Listeria monocytogenes infection | Q40705550 | ||
| Efficient in vivo presentation of Listeria monocytogenes- derived CD4 and CD8 T cell epitopes in the absence of IFN-gamma | Q40753114 | ||
| Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im | Q40767663 | ||
| Priming of memory but not effector CD8 T cells by a killed bacterial vaccine | Q43921694 | ||
| A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy | Q44245789 | ||
| Early programming of T cell populations responding to bacterial infection | Q44560253 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Listeria monocytogenes | Q292015 |
| P304 | page(s) | 3990-4001 | |
| P577 | publication date | 2008-11-06 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity | |
| P478 | volume | 118 |
| Q50545939 | A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. |
| Q35168418 | A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes. |
| Q38617600 | A suicidal strain of Listeria monocytogenes is effective as a DNA vaccine delivery system for oral administration. |
| Q36822696 | Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation |
| Q34871958 | Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus |
| Q33633839 | Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. |
| Q45770616 | Control of innate immune system for cancer therapy |
| Q44483910 | Dendritic cell immunotherapy |
| Q38069183 | Dendritic cell immunotherapy in ovarian cancer |
| Q89347786 | Dendritic cell-based immunotherapy |
| Q39472154 | Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma |
| Q37754014 | Directing dendritic cell immunotherapy towards successful cancer treatment |
| Q37086138 | Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma. |
| Q27021570 | Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy |
| Q35066276 | Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA. |
| Q38617306 | Prospects and progress of Listeria-based cancer vaccines |
| Q35832233 | The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells |
| Q38808249 | Understanding dendritic cell immunotherapy in ovarian cancer |
| Q27490454 | Vaccines: the Fourth Century |
Search more.